Intervacc AB (publ) announced that the first batch of Strangvac, a vaccine against the highly contagious bacterial equine disease Strangles, has been released for sale in Italy. Dechra Pharmaceuticals PLC distributes the vaccine in Italy and in a number of other European countries.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.34 SEK | -0.80% | +3.95% | -31.44% |
04/03 | Intervacc AB Announces Changes in the Nomination Committee | CI |
28/02 | Intervacc's Acting CEO Assumes Role Permanently | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-31.44% | 30.43M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- IVACC Stock
- News Intervacc AB
- Intervacc AB Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy